

1. Record Nr.	UNINA9910141315803321
Titolo	Pharmacotherapy of child and adolescent psychiatric disorders // [edited by] David Rosenberg and Samuel Gershon
Pubbl/distr/stampa	Chichester, West Sussex, : John Wiley & Sons, Inc., 2012
ISBN	9786613654137 9781119961000 1119961009 9781280677205 1280677201 9781119958338 1119958334 9781119958321 1119958326
Edizione	[3rd ed.]
Descrizione fisica	1 online resource (475 p.)
Altri autori (Persone)	RosenbergDavid R GershonSamuel
Disciplina	618.92/8918 618.928918
Soggetti	Pediatric psychopharmacology Antipsychotic drugs
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Pharmacotherapy of Child and Adolescent Psychiatric Disorders; List of Contributors; Foreword; Chapter 1 Historical Perspectives on Child and Adolescent Psychopharmacology; References; Chapter 2 Pharmacoepidemiology of Psychotropic Medications in Youth; Introduction; Prevalence and trends for medications prescribed for ADHD; Nonstimulant medications for ADHD; Antidepressant medication; Antipsychotic medication; Alpha-agonists; Anticonvulsant "mood stabilizers"; Concomitant psychotropic medication; Preschool psychotropic medication use International patterns of psychotropic medication for youthConclusion; References; Chapter 3 Off-Label Prescribing of Drugs in Child and

Adolescent Psychiatry; Introduction; Extent of off-label prescribing; Need for psychoactive drug treatments for children and adolescents; Legislation supporting pediatric drug development; Recommendations to follow when considering off-label prescribing; References; Chapter 4 The Use of Generic Drugs in Pediatric Psychopharmacology; What is a generic drug?; Why are we discussing generic drugs?; Basic requirements for generic drugs

The status of regulations regarding generic drugs and children Abbreviated new drug application (ANDA) requirements; Pediatric assessments of adult drugs (history up to current status); Best Pharmaceuticals for Children Act; Pediatric Research Equity Act; Intersection of requirements for generics and pediatric assessment; Future directions; Concluding thoughts; References; Chapter 5 Psychoactive Drug Use in Children: Basic Concepts in Clinical Pharmacology; Introduction; Basic concepts in pharmacokinetics; Dosing considerations for psychoactive drugs in children; Summary; References

Chapter 6 Psychostimulants Introduction; Epidemiology of stimulant use; Structure and biochemical mechanism of action; Neuroimaging studies of stimulant effects; Studies of short-term efficacy; Studies of long-term efficacy; Clinical use; Common side-effects; Cardiovascular safety issues; Growth suppression; Substance use and diversion; Comparison with nonstimulant treatment; Treatment of comorbidity; Pharmacogenetics; Conclusions; References; Chapter 7 Tricyclic Antidepressants and Monoamine Oxidase Inhibitors for the Treatment of Child and Adolescent Psychiatric Disorders

Tricyclic antidepressants (TCAs) Drug interactions, contraindications; Monoamine oxidase inhibitors (MAOIs); General summary; References; Chapter 8 Selective Serotonin Reuptake Inhibitors (SSRIs); Pharmacokinetics; Initiation and titration; Indications and efficacy; Adverse effects; Withdrawal; References; Chapter 9 Novel (Atypical) Antidepressants; Novel (atypical) antidepressants; General overview; Bupropion; Duloxetine; Mirtazapine; Trazodone; Venlafaxine; Desvenlafaxine; Alternative treatments; Summary; References; Chapter 10 Antipsychotic Agents; Introduction; Chemical properties

Typical antipsychotics

---

## Sommario/riassunto

This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo

---